HLA-F Expression in Motor Neurons for ALS Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for amyotrophic lateral sclerosis (ALS) lack effective methods to address the premature degeneration and death of motor neurons, with the etiology of sporadic ALS remaining largely unknown, and existing treatments fail to provide significant protection against motor neuron toxicity.
Innovation Solution
The development of compounds and compositions that increase the expression of the HLA-F MHC class I molecule in motor neurons, using nucleic acids and viral vectors to administer sequences that promote sustained expression of HLA-F, thereby protecting motor neurons from toxicity induced by ALS astrocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for ALS, then treatment is provided, but they fail to protect motor neurons from toxicity and address premature degeneration
Solution Approach 1:
The patent introduces HLA-F as an intermediary molecule that mediates protection between astrocytes and motor neurons. HLA-F expression in motor neurons acts as a protective barrier against toxic factors secreted by ALS astrocytes, thereby resolving the contradiction by providing a molecular mediator that blocks harmful interactions while maintaining therapeutic effectiveness
Solution Approach 2:
The patent employs preliminary action by using viral vectors to deliver HLA-F coding sequences to motor neurons before significant degeneration occurs. This preventive approach establishes protective HLA-F expression in advance, enabling motor neurons to resist toxicity from ALS astrocytes before damage accumulates, thus improving reliability while addressing harmful factors
2Reliability
If HLA-F expression is increased in motor neurons, then protection against ALS is achieved, but viral vectors and nucleic acid administration are required
Solution Approach 1:
The patent enhances universality by designing a multi-functional system where viral vectors serve multiple purposes: delivering HLA-F coding sequences, enabling sustained expression through integration, and providing targeted delivery to motor neurons. This consolidates multiple functions into a single administrative approach, reducing overall system complexity while achieving reliable protection
Solution Approach 2:
The patent applies parameter changes by modifying the expression level and duration of HLA-F through viral vector-mediated delivery. By controlling viral titer, integration efficiency, and promoter strength, the system optimizes HLA-F expression parameters to achieve maximum protective effect while minimizing the complexity of administration protocols
Data Source
AI summary
The invention relates to compositions, compounds, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to compounds, compositions, methods, and uses for the treatment of amyotrophic lateral sclerosis by increasing the expression of the MHC class I molecule, HLA-F, in motor neurons of the patient.